Verition Fund Management
ONCY

Verition Fund Management’s Oncolytics Biotech ONCY Stock Holding History

Verition Fund Management’s Portfolio ONCY Stock Details ONCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-408,838
Closed -$695K – 1251
2019
Q2 		$695K Buy
+408,838
New +$742K 0.02% 556

Other funds holding ONCY

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SC
Scotia Capital Toronto, Ontario, Canada $24.3B AUM 29.21% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
MFG
Magnus Financial Group New York $1.41B AUM 23.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Comerica Bank
Comerica Bank Dallas, Texas $25.1B AUM 24.68% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Verition Fund Management's ONCY Position: Q3 2019 in Review

Verition Fund Management sold out of Oncolytics Biotech (ONCY) in Q3 2019, closing a stake of 408,838 shares — an estimated $695K sold.

Verition Fund Management first reported a position in ONCY in Q2 2019 and held it in 1 quarter. The position peaked at $695K in Q2 2019. 21 funds tracked by Wall St. Rank hold ONCY as of Q3 2019.

  • Verition Fund Management reported no remaining Oncolytics Biotech position as of Q3 2019 after selling out during the quarter.
  • Verition Fund Management sold 408,838 Oncolytics Biotech shares in Q3 2019, an estimated $695K.
  • Verition Fund Management first reported a position in Oncolytics Biotech in Q2 2019 and held it in 1 quarter.
  • Verition Fund Management's Oncolytics Biotech position peaked at $695K in Q2 2019.
  • 21 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q3 2019.

Based on Verition Fund Management's 13F filing for Q3 2019, filed 14 Nov 2019.